Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Nicole Ilonzo

Vascular Surgery Brooklyn, NY Medical Doctor

NPI 1528486503 CMS profile 8801511

506 6Th St, Brooklyn, NY 11215

Open in the dashboard

General payments

$94,097

553 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Ilonzo of Brooklyn, NY is reported in the CMS Open Payments database as having received $94,097 across 553 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,783 202
2024 General $7,520 86
2023 General $21,444 79
2022 General $16,477 116
2021 General $3,168 62
2020 General $15,703 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Ilonzo
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Nicole Ilonzo were reported at $29,783. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Nicole Ilonzo Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $15,703 $348 $118–$1,110 $114
2021 $3,168 $471 $158–$1,421 $132
2022 $16,477 $725 $222–$2,183 $149
2023 $21,444 $836 $257–$2,440 $160
2024 $7,520 $909 $252–$2,619 $164
2025 $29,783 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Inari Medical, Inc. $35,062 53 payments
  2. Medtronic, Inc. $30,690 313 payments
  3. Medtronic Vascular, Inc. $15,703 8 payments
  4. Bard Peripheral Vascular, Inc. $4,065 3 payments
  5. Stryker Corporation $2,857 54 payments
  6. Penumbra, Inc. $1,083 5 payments
  7. Abbott Laboratories $1,081 25 payments
  8. Cook Medical LLC $929 19 payments
  9. Tactile Systems Technology Inc $828 30 payments
  10. Cagent Vascular LLC $810 24 payments
  11. Other $988 19 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,430 11 payments
  2. Food and Beverage $22,064 496 payments
  3. Consulting Fee $17,944 6 payments
  4. Grant $15,000 1 payment
  5. Travel and Lodging $9,329 38 payments
  6. Education $330 1 payment
Products named General payments · program years 2020–2025
  1. FLOWTRIEVER CATHETER, S $35,928 68 payments
  2. CT THROMBECTOMY SYSTEM KIT $35,651 66 payments
  3. Endurant Aortic Stent Grafts $15,296 5 payments
  4. HawkOne $11,274 84 payments
  5. TurboHawk $2,887 22 payments
  6. IN.PACT Admiral $2,188 26 payments
  7. Endurant Aortic Stent Grafts $1,158 11 payments
  8. Abre $1,147 54 payments
  9. Indigo System $919 4 payments
  10. IN.PACT AV $862 35 payments
  11. Other $12,289 267 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

118

Median for Vascular Surgery: 122

Drug cost

$25,730

Median for Vascular Surgery: $14,135

Branded share of claims

44.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 40 $25,037
Triamcinolone Acetonide Generic 24 $452
Gabapentin Generic 19 $156
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 13 $65
Tramadol Hcl Generic 22 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$128,061

Medicare's payments for the services billed

Medicare patients

302

Average age 74

Services billed

908

182 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 71%
Arthritis 62%
Chronic kidney disease 58%
Heart failure 53%
Ischemic heart disease 52%
Atrial fibrillation 28%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

553 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record